Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1130.3000 10.40 (0.93%)
NSE Oct 10, 2025 15:31 PM
Volume: 1.5M
 

1130.30
0.93%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues increased 18% YoY to | 4436 crore (I-direct estimate: | 4189 crore) mainly due to strong growth in the US and Europe. The US revenue grew 21% YoY to | 2099 crore (I-direct estimate: | 1957 crore) mainly due to launched of limited competition product Sevelamer carbonate (nephrology). Europe revenues grew 37% YoY to | 1114 crore (I-direct estimate: | 997 crore). EBITDA margins improved 58 bps YoY to 25.2% (I-direct estimates:...
Aurobindo Pharma Ltd. is trading below its 200 day SMA of 1144.5
More from Aurobindo Pharma Ltd.
Recommended